Sanofi has bolstered its rare disease business with an agreement to buy Blueprint Medicines and its approved therapy for the blood disorder advanced systemic mastocytosis (ASM).

赛诺菲通过达成收购蓝图医药及其已获批的用于治疗血液疾病晚期系统性肥大细胞增多症（ASM）的疗法，加强了其罕见病业务。

If it goes through, the takeover will give Sanofi rights to Ayvakit/Ayvakyt (avapritinib), a tyrosine kinase inhibitor (TKI) that targets the KIT D816V mutation in ASM, an umbrella term that covers multiple disorders including aggressive systemic mastocytosis, systemic mastocytosis with an associated haematological neoplasm (SM-AHN), and mast cell leukaemia (MCL)..

如果收购成功，赛诺菲将获得Ayvakit/Ayvakyt（阿伐普利尼）的权利，这是一种酪氨酸激酶抑制剂（TKI），针对ASM中的KIT D816V突变，ASM是一个涵盖多种疾病的总称，包括侵袭性系统性肥大细胞增多症、伴有相关血液肿瘤的系统性肥大细胞增多症（SM-AHN）以及肥大细胞白血病（MCL）。

Ayvakit is the only approved medicine for ASM, which causes symptoms like itching, fever, abdominal pain, and nausea, and can also lead to organ damage, bone fractures, and anaemia. People with ASM typically have a life expectancy ranging from six months to around three-and-a-half years.

Ayvakit是唯一获准用于治疗ASM的药物，这种疾病会引起瘙痒、发烧、腹痛和恶心等症状，还可能导致器官损伤、骨折和贫血。ASM患者的预期寿命通常为六个月到三年半左右。

The acquisition, which also includes a pipeline of drugs headed by ASM follow-up elenestinib in phase 3 testing and wild-type KIT inhibitor BLU-808, 'represents a strategic step forward in our rare and immunology portfolios,' said Sanofi's chief executive, Paul Hudson. 'It enhances our pipeline and accelerates our transformation into the world's leading immunology company.'.

赛诺菲首席执行官保罗·哈德森表示：“此次收购还包括由ASM后续药物elenestinib领导的第三阶段测试的药物管道和野生型KIT抑制剂BLU-808，这代表了我们在罕见病和免疫学产品组合中的战略性进展。它增强了我们的研发管线，并加速了我们向全球领先的免疫学公司转型。”

The $129-per-share, all-cash deal also includes a pair of additional contingent value rights, worth $2 and $4 apiece, that respectively cover development and regulatory milestones for BLU-808, which is in early clinical development for chronic urticaria and allergic rhinoconjunctivitis and is also being studied for allergic asthma and mast cell activation syndrome..

每股129美元的全现金交易还包括两项额外的或有价值权，分别价值2美元和4美元，分别涵盖BLU-808在慢性荨麻疹和过敏性鼻结膜炎的早期临床开发中的开发和监管里程碑，该药物还正在研究用于过敏性哮喘和肥大细胞活化综合征。

Assuming BLU-808 meets those targets, the total value of the transaction would grow to around $9.5 billion, according to Sanofi.

据赛诺菲称，假设BLU-808达到这些目标，本次交易的总价值将增长到约95亿美元。

Hudson has previously said he was looking for M&A deals this year to shore up its already-strong position in immunology, driven by $14 billion-plus blockbuster

胡德森此前曾表示，他正在寻找今年的并购交易，以巩固其在免疫学领域已经强大的地位，这一地位得益于价值超过140亿美元的重磅药物。

Dupixent

Dupixent

(dupilumab), with the help of €10 billion ($11/4 billion) in proceeds from the sale of its controlling stake in consumer healthcare business

（dupilumab），并利用出售其在消费者健康业务中控股权所获得的100亿欧元（114亿美元）收益。

Opella

奥佩拉

, which closed last month.

上个月关闭了。

'Sanofi still retains a sizeable capacity for further acquisitions,' said the CEO, who noted that the deal 'complements recent acquisitions of early-stage medicines that remain our main field of interest.' Just last week, the French group agreed to buy

“赛诺菲仍然拥有进行进一步收购的相当大的能力，”首席执行官表示，并指出该交易“是对我们最近收购的早期药物的补充，这些仍然是我们主要感兴趣的领域。”就在上周，这家法国集团同意收购

Vigil Neuroscience

警觉神经科学公司

and its TREM2 drug candidate for Alzheimer's disease for around $470 million.

其针对阿尔茨海默病的TREM2候选药物，交易金额约为4.7亿美元。

Cambridge, Massachusetts-based Blueprint recorded nearly $150 million in Ayvakit revenues in the first quarter of this year and has said it is expecting full-year sales to be up to $720 million en route to $2 billion or more by the end of the decade.

总部位于马萨诸塞州剑桥市的Blueprint今年第一季度录得近1.5亿美元的Ayvakit收入，并表示预计全年销售额将达到7.2亿美元，到本十年末有望达到20亿美元或更多。

The company's CEO, Kate Haviland, said that Sanofi's 'exceptional leadership in rare disease and immunology' makes it an ideal acquirer and the deal marks a 'new chapter' for Blueprint.

该公司首席执行官凯特·哈维兰表示，赛诺菲在罕见病和免疫学领域的“卓越领导地位”使其成为理想的收购者，这笔交易标志着蓝图公司“新篇章”的开始。